Abstract 167P
Background
The study aimed to evaluate baseline and dynamic changes of serum neutrophil-to-lymphocyte ratio (NLR) level as biomarkers of response to anti-PD-1/PD-L1 blockade combined with anti-VEGF or tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma (aHCC) patients and the potential relationship between NLR and serum cytokines.
Methods
We collected NLR level at baseline and week 3 since initial treatment as well as baseline serum cytokines in patients with aHCC treated with immune-targeted combination therapy from October 2018 to November 2021. The cutoff of baseline NLR was defined by median level. We defined both baseline NLR ≤ 2.63 as well as NLR decrease at week 3 as group1 (n = 30), baseline NLR ≤ 2.63 while NLR increase at week 3 as group2 (n = 27), baseline NLR > 2.63 while NLR decrease at week 3 as group3 (n = 38), both baseline NLR>2.63 as well as NLR increase at week 3 as group4 (n = 14).
Results
A total of 132 patients with aHCC received the immune-targeted combination therapy were included. Baseline high NLR was significantly associated with worse progression-free survival (PFS) (5.4 vs. 14.1 months, p < 0.001) and overall survival (OS) (11.3 vs. 27.7 months, p < 0.001), even after multivariate analysis. NLR level decreased significantly at week 3 in patients with complete response or partial response (CR/PR) (baseline vs. week3: 2.30 vs. 1.96, p = 0.006), no significant difference was shown in patients with progression disease (PD) (n = 18) (baseline vs. week3: 3.80 vs. 2.90, p = 0.157). Patients in group4 showed the worst treatment response, with no patients achieved CR/PR. Cytokines analysis showed that patients with baseline high NLR had significantly higher level of baseline serum IL-8 than those with low NLR (5.66 vs. 2.05 pg/ml, p = 0.001). Patients with baseline high IL-8 showed worse PFS (5.5 vs. 11.4 months, p =0.047) and OS (13.5 vs. 26.4 months, p = 0.001).
Conclusions
NLR is an independent prognostic factor for aHCC, the combination of dynamic change and baseline NLR may assist in screening out patients who are difficult to benefit from immune-targeted therapy. High baseline NLR may correlate with high baseline serum IL-8.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The CAMS Innovation Fund for Medical Sciences; The Translational Research Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences; Beijing Natural Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract